NUVB
Nuvation Bio Inc. (NUVB) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Runway
Revenue base remains small, leaving room for multi-year scaling if adoption continues.
Gross margin is very high at 93.9%, which supports operating leverage over time.
Profitability
TTM margins remain deeply negative, with EBIT margin at -76.0% and net margin at -88.2%.
Return metrics are still poor, including ROIC at -20.7% and ROE at -49.7%.
Financial Strength
Liquidity is very strong, with a current ratio of 8.37 and quick ratio of 8.14.
Balance sheet leverage remains manageable, with debt-to-equity at 0.99 and net debt to EBITDA near flat at 0.05.
Cash Generation
Operating cash flow and free cash flow remain negative, with FCF yield at -3.8% and OCF yield at -9.5%.
Cash conversion remains weak, reflecting a negative operating cash flow ratio and persistent losses.
Valuation
The stock still trades at a rich sales multiple, with EV/Sales at 12.7x.
Valuation is hard to anchor on earnings or cash flow because both remain negative.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Nuvation Bio Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

